Facebook
Facebook
This 2009 NCDEU Poster Session was published in September 2009 and is eligible for AMA PRA Category 1 Credit through March 31, 2010. The latest review of this material was August 2009.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
After completing this educational activity, you should be able to:
This special 2009 NCDEU Annual Meeting Poster Session was developed based on our assessment of the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on current research relevant to clinical practice.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:
Over the past 3 years, Dr Carpenter has been a consultant or member of the advisory boards for Abbott, Bristol-Myers Squibb, Cyberonics, Medtronic, Novartis, Pfizer, Wyeth, Sepracor, AstraZeneca, and Neuronetics; has received grant/research support from the NIMH, NARSAD, Pfizer, UCB, Sepracor, Cyberonics, the Department of Defense, Medtronic, and Neuronetics; has received honoraria for CME from the APA, Wyeth, Cyberonics, and AstraZeneca; has been a member of the speakers bureaus for AstraZeneca, Pfizer, and Cyberonics; and has received travel support from Neuronetics.
Dr Bedard has been a member of the speakers/advisory boards for Shire.
Dr Cucchiaro is an employee of Dainippon Sumitomo Pharma America, Inc.
Dr Garcia has received material support from Neuronetics.
Dr Grant has received grant/research support from Forest and has received royalties from American Psychiatric Publishing, Inc.
Dr Halperin has been a consultant for Shire.
Dr Loebel is an employee of Dainippon Sumitomo Pharma America, Inc.
Dr Newcorn has received grant/research support from Eli Lilly and McNeil Pediatrics, and has been a consultant for or a member of the speakers/advisory boards for McNeil, AstraZeneca, Eli Lilly, Novartis, Shire, and Psychogenics.
Ms Ogasa is an employee of Dainippon Sumitomo Pharma America, Inc.
Ms Philips is an employee of Dainippon Sumitomo Pharma America, Inc.
Dr Silva is an employee of Dainippon Sumitomo Pharma America, Inc.
Dr Stein has received grant/research support from Eli Lilly and Ortho McNeil.
Dr Tyrka has received grant/research support from Cyberonics, the Department of Defense, Medtronic, the NIH, Pfizer, Sepracor, and UCB, and has received honoraria for CME from Lundbeck and Takeda.
Dr Xu is an employee of Dainippon Sumitomo Pharma America, Inc.
Drs Kim, Philip, Pierce, Price, and Whiteley, Ms Flynn, and Mr Odlaug have no personal financial relationships to disclose relative to this presentation.
In this 2009 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Administration–labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This 2009 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP), and a member of the External CME Advisory Board has reviewed this poster session to determine whether the material is evidence-based and objective.
This 2009 NCDEU Poster Session is derived from the 49th Annual NCDEU Meeting, which was held June 29–July 2, 2009, in Hollywood, Florida, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.
Psychiatrist.com Home
Keyword Search